LY-354740 (Eli Lilly)
Related Experiment Video
Updated: Sep 25, 2026
09:12
MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
Published on: December 21, 2011
1Institute of Pharmacology, Polish Academy of Sciences, 31-343 Krakow, Smetna 12, Poland. nfpilc@cyf-kr.edu.pl
Idrugs : the Investigational Drugs Journal
|June 6, 2003
Abstract:
Lilly is developing LY-354740, the lead compound in a series of derivatives of the metabotropic glutamate receptor group II agonist L-CCG-1, for the potential treatment of anxiety [212536], [276941], [276942].
